The efficacy, pharmacokinetics, and safety of a nevirapine to rilpivirine switch in virologically suppressed HIV-1-infected patients.
about
Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy.Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans.
P2860
The efficacy, pharmacokinetics, and safety of a nevirapine to rilpivirine switch in virologically suppressed HIV-1-infected patients.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The efficacy, pharmacokinetics ...... essed HIV-1-infected patients.
@en
type
label
The efficacy, pharmacokinetics ...... essed HIV-1-infected patients.
@en
prefLabel
The efficacy, pharmacokinetics ...... essed HIV-1-infected patients.
@en
P2093
P1476
The efficacy, pharmacokinetics ...... essed HIV-1-infected patients.
@en
P2093
Bart J A Rijnders
Casper Rokx
David Burger
Maren Blonk
P356
10.1097/QAI.0000000000000363
P407
P577
2015-01-01T00:00:00Z